Lamotrigine for Bipolar Disorder: Benefits and Serious Safety Warnings
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Lamotrigine is a prescription anticonvulsant used in bipolar disorder primarily to help prevent future mood episodes, particularly depressive recurrence. It occupies a specific place in treatment: the U.S. Food and Drug Administration (FDA) approves Lamictal (lamotrigine) for maintenance treatment of bipolar I disorder in adults after acute episodes have been treated. Its value for an acute bipolar depressive episode is evaluated differently across professional guidelines. It is not an appropriate treatment for quickly controlling acute mania. These distinctions, and the drug's potentially life-threatening skin reactions, determine whether it is a reasonable option for an individual patient. FDA prescribing information; CANMAT/ISBD guidelines.
The central safety principle is simple: lamotrigine must be prescribed with a carefully chosen, gradually escalating regimen, adjusted for interacting medicines. A rash during treatment can require urgent medical evaluation because an early harmless-looking eruption may be difficult to distinguish from a developing severe drug reaction. This article explains the evidence, indications, risk factors, warning signs, monitoring, and questions worth discussing with a qualified prescriber. FDA boxed warning.
For additional clinical context, see Valproate for Bipolar Disorder: Uses, Risks, and Reproductive Safety.
What is lamotrigine, and why is it used for bipolar disorder?
Lamotrigine is an antiseizure medicine also used as a mood-stabilizing treatment. Its precise mood-related mechanism is not established. Pharmacologically, it influences voltage-sensitive sodium channels and excitatory neurotransmission, including glutamate release, but these observations do not by themselves explain which patient will benefit clinically. Lamotrigine differs from drugs typically used to rapidly suppress a manic episode. FDA prescribing information.
Bipolar I disorder involves at least one manic episode; bipolar II disorder includes hypomania and major depressive episodes without a history of full mania. Treatment choices require a longitudinal diagnostic assessment: clinicians evaluate episode duration, severity, functional impairment, past responses, possible medication or substance effects, and whether depression occurs within a bipolar rather than unipolar course. Changes in mood alone or an online screening result do not establish a diagnosis. Our bipolar disorder overview provides the diagnostic context. NIMH overview.
Lamotrigine is often considered when preventing depressive recurrence is a major clinical priority, including in a person whose history contains substantial bipolar depression. The choice still depends on previous mania, mixed symptoms, adherence, other medications, medical history, reproductive planning, and the ability to complete slow titration. The general bipolar medication guide compares the roles of several medicine classes. CANMAT/ISBD guidelines.
FDA approval and clinical guidelines: an essential distinction
FDA approval is based on specified indications and submitted evidence. The U.S. Lamictal label authorizes maintenance treatment of bipolar I disorder to delay mood episodes in adults whose acute episodes have been managed using standard therapy. It explicitly says that effectiveness for acute mood episodes has not been established and that treatment of acute manic or mixed episodes is not recommended. A prescription for another bipolar indication may be an evidence-informed off-label decision by a clinician; a guideline recommendation is not an expansion of the FDA-approved indication. Current FDA-approved labeling via DailyMed.
The 2023 CANMAT/ISBD evidence update places lamotrigine among first-line options for acute bipolar I depression and maintenance of bipolar I disorder, while identifying it as a second-line option for acute bipolar II depression and a first-line maintenance option for bipolar II disorder. The 2023 VA/DoD guideline is more cautious about acute bipolar depression: it finds insufficient evidence for or against lamotrigine alone and makes a weak recommendation for lamotrigine combined with lithium or quetiapine. Differences in grading systems, selected outcomes, and evidence interpretation explain why recommendations should be read in their exact context. CANMAT/ISBD; VA/DoD clinical practice guideline.
The responsible interpretation is that lamotrigine has a substantial maintenance-treatment role, especially concerning depression, and a debated but plausible role in selected acute bipolar-depression strategies. Neither position supports using it as emergency treatment for mania, psychosis, a rapidly deteriorating mixed episode, or an immediate threat to safety. NICE CG185 recommendations.
Benefits of lamotrigine by phase of bipolar disorder
Maintenance treatment and preventing depressive recurrence
The strongest established role is long-term relapse prevention in bipolar I disorder. Two influential randomized, double-blind, approximately 18-month maintenance trials compared lamotrigine, lithium, and placebo after patients had been stabilized. They found that lamotrigine prolonged time to intervention for a mood episode compared with placebo, with a relatively stronger profile for preventing depressive rather than manic recurrence; lithium showed a stronger profile for mania prevention in these trial populations. The findings are about preventing episodes over time, not promising complete protection for every patient. Bowden and colleagues, 2003; Calabrese and colleagues, 2003.
A 2025 meta-analysis of randomized trials found a reduced risk of emerging bipolar depressive symptoms during prophylaxis with lamotrigine compared with placebo (risk ratio 0.78, 95% confidence interval 0.63–0.98). This is a population-level result; individuals may still relapse, experience hypomania or mania, or require combination treatment. Arnone and colleagues, 2025.
Maintenance planning should consider which type of episode previously caused the greatest impairment. Someone with recurrent mania may need an antimanic preventive component rather than lamotrigine alone. For broader principles, see bipolar maintenance treatment. VA/DoD guideline.
Acute bipolar depression: genuine evidence with important limitations
Lamotrigine is widely discussed for bipolar depression because its evidence profile differs from that of conventional antidepressants and antimanic agents. Individual acute trials have produced inconsistent findings; an individual-patient-data meta-analysis identified a modest average benefit, with stronger apparent effects in participants with greater initial depressive severity. A newer 2025 meta-analysis reported a small pooled acute bipolar-depression benefit in monotherapy versus placebo (standardized mean difference 0.155, 95% confidence interval 0.005–0.305). A statistically detectable average benefit of this size does not mean rapid recovery or a large effect for a typical patient. Geddes and colleagues, 2009; Arnone and colleagues, 2025.
Guidelines assess both efficacy and how a drug can be delivered. Lamotrigine's necessary slow titration delays reaching a clinician-selected therapeutic regimen, which limits its usefulness when an episode calls for prompt relief. That practical limitation helps explain why a clinician may prefer another treatment, use lamotrigine as an adjunct, or focus on its longer-term preventive value. The comparative treatment evidence is reviewed in our bipolar depression treatment guide. VA/DoD guideline; NICE CG185.
Acute mania, mixed episodes, and psychosis
Lamotrigine is not recommended for treating acute mania or mixed episodes. It lacks the antimanic evidence and onset characteristics needed for managing rapidly escalating energy, reduced need for sleep, severe impulsivity, agitation, dangerous judgment, or mania with psychotic symptoms. NICE expressly advises against offering lamotrigine for mania. Acute-care treatment typically requires a separate clinician-led plan involving medicines with specific antimanic evidence and, when necessary, urgent hospital-based assessment. NICE CG185; VA/DoD guideline.
If someone taking lamotrigine develops clear manic symptoms, that event warrants reassessment of the whole treatment plan; simply increasing lamotrigine is not an evidence-based substitute for acute antimanic care. See treatment for acute mania. CANMAT/ISBD.
Bipolar II disorder
Bipolar II disorder is defined by hypomania and major depression, and its depressive burden can be substantial. CANMAT/ISBD considers lamotrigine a first-line maintenance option and a second-line acute-depression option for bipolar II disorder. This does not extend the U.S. FDA bipolar maintenance indication, which is specifically bipolar I, and does not justify treating bipolar II as a mild version of bipolar I. CANMAT/ISBD.
How strong is the evidence?
The overall evidence base comprises randomized trials, long-term prevention studies, and evidence syntheses. The 2024 systematic review by Haenen and colleagues included randomized and cohort investigations and examined acute depression, mania or hypomania, and maintenance separately. It supports treating these phases as distinct questions. Population differences, enrichment designs in maintenance trials, varying comparison treatments, limited bipolar II datasets, and study duration affect how confidently any result applies to an individual. Haenen and colleagues, 2024.
A maintenance study that enrolls people after stabilization may estimate benefits for those able to reach and tolerate that phase. Its results should not be used to predict the first few weeks of treatment, nor should acute depression scores be presented as proof of relapse prevention. Similarly, absence of an FDA acute indication and a guideline's off-label recommendation can coexist without contradiction. FDA label; CANMAT/ISBD.
Why lamotrigine must be started slowly
One of lamotrigine's defining safety requirements is gradual dose escalation under medical supervision. The initial regimen and every subsequent step depend on the person's other medicines and clinical circumstances. Valproate can substantially increase lamotrigine exposure; certain enzyme-inducing medicines can lower exposure; estrogen-containing hormonal products can also alter levels. Consequently, another patient's schedule, a remembered previous schedule, or an online dose table is not a safe substitute for an individualized prescription. FDA prescribing information, dosing and interactions.
Taking more than the recommended initial amount, escalating faster than the prescribed schedule, or combining lamotrigine with valproate without the required adjustment raises concern about severe rash. The slow start is a risk-reduction measure, even when symptoms make a person understandably eager for faster improvement. No patient should accelerate a titration plan to speed up an antidepressant effect. FDA boxed warning.
Serious skin rash: the FDA boxed warning
Stevens–Johnson syndrome and toxic epidermal necrolysis
The FDA requires a boxed warning because lamotrigine can cause life-threatening skin reactions, including Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and deaths have been reported. These reactions may involve painful red or purple rash, blistering, peeling skin, and painful sores affecting the mouth, eyes, or other mucous membranes. Fever and flu-like symptoms can accompany serious reactions. The severity is a reason for immediate assessment, not a reason to try diagnosing the rash at home. FDA prescribing information.
A new rash while taking lamotrigine requires prompt contact with the prescribing clinician, because clinicians cannot reliably determine from early appearance alone which rashes will become dangerous. FDA labeling directs discontinuation at the first sign of rash unless it is clearly not drug-related; the response, assessment, and possible resumption must be clinician-directed. A spreading or painful rash, blistering, peeling, mouth or eye lesions, fever with rash, or a person who appears acutely unwell warrants emergency medical evaluation. FDA boxed warning and Medication Guide.
When can severe rash occur, and how common is it?
Most reported life-threatening rashes begin within two to eight weeks after starting lamotrigine, although reactions can occur later. In adult bipolar clinical trials the FDA label reports serious rash requiring hospitalization and treatment discontinuation in a small proportion of patients; estimates depend on study population, indication, and concomitant treatment. The boxed warning provides indication-specific incidence information and notes higher rates in pediatric epilepsy populations. A precise rate from one population should not be transferred unchanged to a person treated for bipolar disorder. FDA labeling, boxed warning and section 5.1.
Risk is influenced by valproate coadministration, excessive starting doses, and faster-than-recommended escalation. Neither following every rule nor having previously tolerated lamotrigine makes the risk zero. Past hypersensitivity and a previous lamotrigine-associated rash are especially important to discuss before any proposed re-exposure. FDA labeling.
Other serious reactions and urgent warning signs
Severe adverse reactions may affect more than skin. Lamotrigine labeling warns about drug reaction with eosinophilia and systemic symptoms (DRESS), a multisystem hypersensitivity syndrome that may involve fever, lymph-node enlargement, facial swelling, liver or kidney inflammation, or blood abnormalities, sometimes before a prominent rash is visible. It also warns about hemophagocytic lymphohistiocytosis (HLH), a rare but potentially fatal immune reaction associated with persistent fever, enlarged organs, abnormal blood counts, and systemic illness. These presentations call for immediate medical evaluation. FDA labeling, sections 5.2 and 5.3.
Another warning is aseptic meningitis: severe headache, fever, stiff neck, sensitivity to light, nausea, or confusion can appear and require urgent assessment. Blood-cell abnormalities and liver injury are additional uncommon but clinically consequential concerns. Symptoms alone do not identify their cause, so evaluation must consider infection and other medical emergencies as well as a medication reaction. FDA labeling, warnings and precautions.
The FDA has also identified an arrhythmia concern in susceptible patients with clinically important structural or functional heart disease or specific conduction disorders. A prescriber should know about relevant heart diagnoses, prior unexplained fainting, and potentially interacting sodium-channel-blocking medicines. New fainting, sustained palpitations, chest pain, or breathing difficulty calls for appropriate urgent evaluation. FDA cardiac safety communication.
All antiseizure medicines, including lamotrigine, carry a warning about suicidal thoughts or behavior. Clinicians should monitor notable changes in mood, agitation, suicidal thinking, or behavior while also recognizing that bipolar depression itself carries important risk. In an immediate crisis, seek local emergency services or urgent crisis care rather than relying on a routine medication appointment. FDA labeling; VA/DoD bipolar guideline.
Common side effects and everyday tolerability
More common adverse effects reported with lamotrigine include dizziness, headache, nausea, blurred or double vision, sleepiness or insomnia, tremor, and problems with coordination. The pattern depends partly on the population, dose, and concomitant medicines. Dizziness, visual disturbance, or impaired coordination can interfere with driving and tasks requiring alertness; a person should discuss such effects with their clinician before undertaking potentially hazardous activities. FDA adverse-reaction tables and Medication Guide.
Many patients and clinicians consider lamotrigine partly because its adverse-effect profile differs from those of lithium and various antipsychotic medicines. A generally different metabolic or sedative profile, however, should not be translated into a promise of no weight change, no cognitive effects, or effortless tolerability. A useful review asks whether the medication reduces episode burden and supports daily functioning while maintaining an acceptable safety profile. CANMAT/ISBD safety and monitoring guidance.
Drug interactions: valproate, other antiseizure drugs, and hormonal contraception
Valproate inhibits lamotrigine metabolism and increases lamotrigine concentrations and half-life. Their coadministration requires a substantially different, slower clinician-directed lamotrigine schedule. Starting or stopping valproate in someone already taking lamotrigine also changes the interaction and may require adjustment. A medication list should include generic and brand names, since the interaction can be overlooked when two prescriptions were written by different clinicians. FDA prescribing information.
Conversely, medications such as carbamazepine, phenytoin, phenobarbital, and primidone can increase lamotrigine clearance. The treatment plan needs re-evaluation when an interacting medicine is introduced, removed, or changed. That concern extends to medicines prescribed for epilepsy or other conditions, even when lamotrigine is being used for bipolar disorder. FDA interactions table.
Estrogen-containing oral contraceptives and other estrogen-containing products can lower lamotrigine blood concentrations, while stopping estrogen exposure can cause concentrations to rise and increase adverse effects. Changes during a contraceptive pill-free interval may also matter. People should inform both psychiatric and reproductive-health clinicians before beginning, stopping, or altering an estrogen-containing method; the safe response involves coordination, not independent dose experimentation. FDA label, estrogen-containing products.
Baseline assessment and follow-up monitoring
Before prescribing lamotrigine, a clinician should confirm the bipolar diagnosis and treatment phase, take a medication and allergy history, assess previous drug rashes, review medical conditions and pregnancy intentions, and establish how treatment response and emerging mania will be assessed. NICE recommends a baseline full blood count, urea and electrolytes, and liver function tests when starting lamotrigine. These measurements help establish context; they cannot predict or rule out a future SJS/TEN reaction. NICE CG185.
Unlike lithium, lamotrigine does not ordinarily require routine serum levels to achieve a universally accepted bipolar therapeutic range. The FDA label states that a therapeutic plasma-concentration range has not been established. Particular scenarios, such as changing estrogen exposure or pregnancy, may justify individualized level monitoring as part of specialist care. The core ongoing checks are skin and systemic symptoms, medication changes, adverse effects, depressive and manic symptoms, adherence, and functional progress. FDA label; NICE CG185.
Review appointments should be frequent enough during initiation to identify rash and other adverse effects, assess whether the stepwise plan is being followed, and decide whether emerging depression or mania requires another intervention. Once a person is stable, visits still assess recurrence, sleep patterns, medication access, and the changing balance of benefits and harms. No one laboratory test substitutes for longitudinal clinical monitoring. VA/DoD guideline.
Pregnancy, postpartum care, breastfeeding, and reproductive planning
Pregnancy-related decisions require specialized assessment of both medication exposure and the risks associated with recurrent bipolar episodes. Lamotrigine concentrations can fall during pregnancy because clearance increases, then rise rapidly after delivery. Clinical symptoms and, when appropriate, individualized therapeutic drug monitoring can guide specialist adjustments. Stopping an effective psychiatric medicine abruptly during pregnancy may also cause harm through relapse. Pregnancy planning is best discussed before a medication change, with coordinated psychiatric and obstetric care. ACOG Clinical Practice Guideline No. 5; FDA label.
Lamotrigine crosses the placenta and enters breast milk. Decisions about use while pregnant or breastfeeding should reflect diagnosis, episode severity, alternatives, previous stability, infant factors, and the current evidence on outcomes. Breastfed infants exposed to lamotrigine may require monitoring for rash, apnea, poor feeding, or unusual sleepiness. A general statement that a drug is safer than another drug does not establish that it is appropriate for every pregnancy. FDA pregnancy and lactation information; ACOG guideline.
Children, adolescents, older adults, and medical comorbidity
The FDA bipolar maintenance indication for lamotrigine is for adults; safety and effectiveness for bipolar disorder in patients younger than 18 years have not been established by its prescribing information. Pediatric epilepsy experience cannot automatically be used to claim an equivalent bipolar benefit. Specialist pediatric diagnosis and monitoring are particularly important because rashes can be more frequent in younger patients, and family decision-making involves developmental needs and school functioning. FDA labeling, pediatric use; CANMAT/ISBD.
Older adults may have additional comorbidities, altered medication clearance, and more complex combinations of prescriptions. Moderate or severe hepatic impairment and significant renal impairment can affect dose planning according to labeling. The exact adjustment and monitoring strategy belongs to the treating clinician. Relevant heart disease and conduction abnormalities also matter when evaluating the FDA cardiac warning. FDA special-population guidance.
Missed doses, treatment interruption, and discontinuation
Interruptions in lamotrigine therapy create a specific safety problem: after a sufficiently long gap, resuming the previous maintenance amount may bypass the gradual restart needed to limit rash risk. FDA labeling instructs prescribers to consider restarting with initial dosing recommendations when treatment was interrupted for more than approximately five half-lives. The practical number of elapsed days can vary with interacting medicines because lamotrigine's half-life changes. A person who missed several doses should contact a pharmacist or prescriber before restarting, rather than doubling up or automatically using the former dose. FDA labeling, restarting therapy.
Discontinuation also deserves planning. The FDA label generally recommends a taper over at least two weeks unless safety concerns require faster withdrawal. A serious suspected hypersensitivity reaction is a different scenario and may require immediate discontinuation under emergency medical guidance. In ordinary long-term care, unplanned stopping can also remove protection against future mood episodes. See our article on stopping bipolar medication safely. FDA label.
How does lamotrigine compare with lithium and antipsychotics?
Lamotrigine, lithium, and antipsychotic medicines are not interchangeable for every episode phase. Lithium has evidence for both antimanic prevention and maintenance treatment, with distinct kidney, thyroid, serum-level, and interaction monitoring. Lamotrigine has a clearer preventive profile for bipolar depression than for mania and emphasizes careful skin-reaction surveillance rather than a standardized bipolar serum target. See our lithium guide. Bowden and colleagues, 2003; CANMAT/ISBD.
Some antipsychotics have controlled-trial evidence for acute mania, certain bipolar depressive episodes, maintenance, or combinations of these indications, depending on the specific medication. Their relevant monitoring may include weight, blood glucose, lipids, movement symptoms, sedation, and other agent-specific risks. Choosing a treatment therefore means identifying a diagnosis and episode phase before comparing drugs; a favorable side-effect profile is not a substitute for efficacy in the phase being treated. CANMAT/ISBD; NICE CG185.
Combination treatment may be appropriate when one medicine addresses depressive prevention and another provides antimanic protection, or when an acute episode requires a different approach. Such decisions must account for interaction risks, adherence, cumulative adverse effects, and previous individual response. The evidence for combining lamotrigine with lithium or quetiapine in acute bipolar depression is specifically addressed in the VA/DoD guideline and should not be extended without evidence to arbitrary combinations. VA/DoD guideline.
What improvement can patients realistically expect?
A useful treatment target extends beyond a short-term mood rating. A clinician and patient may examine recurrence of depressive episodes, time between episodes, severity, sleep and wakefulness, work or school functioning, relationships, adverse effects, and sustained adherence. Improvement in one domain does not guarantee protection in others. Identifying the predominant episode polarity and documenting early warning signs helps determine whether the maintenance strategy is achieving its intended purpose. CANMAT/ISBD.
Lamotrigine is usually one part of a broader management plan involving accurate diagnosis, psychosocial education, sleep regularity, relapse monitoring, and treatment of comorbid conditions where appropriate. Patients and families should understand which symptoms require routine review, which require an urgent appointment, and which suggest an emergency. This remains important even after long symptom-free periods. NICE CG185.
Questions to discuss with the prescribing clinician
Before starting, ask which phase of bipolar illness is being treated, whether the use is on-label or off-label, which relapse pattern lamotrigine is intended to prevent, and what alternative medicines would cover acute mania if it emerged. Review all current prescriptions, hormonal contraception, previous rashes, pregnancy or breastfeeding plans, medical conditions, and drug allergies. Ask for a written titration schedule and a clear plan for missed doses, rash, fever, or a change in other medication. FDA Medication Guide.
During follow-up, discuss whether symptoms are improving in the intended phase, whether function has changed, and whether side effects or new medicines change the balance of benefit and risk. If depression worsens, a person develops markedly reduced need for sleep with unusual energy and risky activity, or suicidal thoughts emerge, the care team should reassess promptly. Severe mania, psychosis, danger to self or others, or a serious suspected drug reaction calls for urgent or emergency care according to local services. VA/DoD guideline.
Frequently asked questions
Is lamotrigine an antidepressant?
Lamotrigine is classified as an antiseizure drug used in mood-disorder treatment. It can have antidepressant-related benefits in bipolar disorder, particularly in preventing depressive relapse, but it is not a conventional antidepressant and its efficacy differs across acute and maintenance contexts. FDA label; Arnone and colleagues.
Can lamotrigine treat a manic episode?
It is not recommended as an acute antimanic treatment. If a manic or dangerous mixed state develops, timely clinical reassessment and phase-appropriate treatment are needed. NICE CG185.
How long does lamotrigine take to work for bipolar depression?
There is no dependable universal timeline. Clinicians must increase it gradually for safety; symptom change depends on the episode, the regimen, concurrent treatment, and individual response. The slow titration also matters when weighing lamotrigine against treatments intended to relieve an acute episode more rapidly. FDA label; VA/DoD guideline.
Is every rash a severe allergic reaction?
No. Many rashes are ultimately less serious, but severity can be difficult to determine at the beginning. The FDA advises discontinuation at the first sign unless the rash is clearly unrelated; prompt medical assessment is essential, with emergency care for skin pain, blistering, mucosal lesions, fever, or systemic illness. FDA boxed warning.
Does taking lamotrigine with valproate increase the risk of rash?
Yes. Valproate increases lamotrigine exposure and is a recognized risk factor in the boxed warning. Only a clinician should coordinate the combination, its slower lamotrigine titration, and changes in either medicine. FDA label.
Does lamotrigine require blood tests like lithium?
There is no established universal therapeutic lamotrigine blood concentration for bipolar disorder and no lithium-style routine concentration target. Baseline medical tests and clinical monitoring remain important; levels may be considered in special circumstances such as pregnancy or interactions. FDA label; NICE CG185.
Can birth control change how lamotrigine works?
Estrogen-containing contraception can decrease lamotrigine concentration, and stopping it may increase exposure. A clinician should coordinate contraceptive changes and medication review, including around pill-free intervals when applicable. FDA label.
Can I restart my usual dose after a break?
Do not assume the old dose is safe. Longer interruptions may require re-titration, and the relevant interval depends on interacting medicines. Contact the prescriber or pharmacist before restarting after multiple missed doses. FDA label.
Can lamotrigine be used during pregnancy?
An individualized specialist risk–benefit assessment is required. Clearance can change during pregnancy and after delivery, potentially altering exposure, and untreated or recurrent bipolar illness also has consequences. Coordinate medication and monitoring decisions with obstetric and psychiatric clinicians. ACOG guideline.
Does lamotrigine cure bipolar disorder?
Lamotrigine is used to treat and help prevent episodes; it is not a cure and does not eliminate the need for ongoing assessment. Long-term management responds to individual episode patterns, tolerability, relapse risk, and changing life circumstances. NIMH bipolar overview; CANMAT/ISBD.
Related Articles
References
American College of Obstetricians and Gynecologists (ACOG). (2023). Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum: Clinical Practice Guideline No. 5. Official guideline.
Arnone, D., Östlundh, L., Mosa, M., MacDonald, B., Oldershaw, J., Qassem, T., & Young, A. H. (2025). Efficacy of lamotrigine in the treatment of unipolar and bipolar depression: Meta-analysis of acute and maintenance randomised controlled trials. Pharmaceuticals, 18(10), 1590. DOI: 10.3390/ph18101590.
Bowden, C. L., Calabrese, J. R., Sachs, G., Yatham, L. N., Asghar, S. A., Hompland, M., Montgomery, P., Earl, N., Smoot, T. M., & DeVeaugh-Geiss, J. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry, 60(4), 392–400. DOI: 10.1001/archpsyc.60.4.392.
Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O. P., Montgomery, P., Ascher, J., Paska, W., Earl, N., & DeVeaugh-Geiss, J. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry, 64(9), 1013–1024. DOI: 10.4088/JCP.v64n0906.
Geddes, J. R., Calabrese, J. R., & Goodwin, G. M. (2009). Lamotrigine for treatment of bipolar depression: Independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry, 194(1), 4–9. DOI: 10.1192/bjp.bp.107.048504.
Haenen, N., Kamperman, A. M., Prodan, A., Nolen, W. A., Boks, M. P., & Wesseloo, R. (2024). The efficacy of lamotrigine in bipolar disorder: A systematic review and meta-analysis. Bipolar Disorders. DOI: 10.1111/bdi.13452.
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4). DOI: 10.1176/appi.focus.20230009.
National Institute for Health and Care Excellence (NICE). (2014, updated). Bipolar disorder: Assessment and management (CG185). Official recommendations.
U.S. Department of Veterans Affairs & U.S. Department of Defense (VA/DoD). (2023). VA/DoD Clinical Practice Guideline for the Management of Bipolar Disorder. Full guideline PDF.
U.S. Food and Drug Administration (FDA). (2021). Studies show increased risk of heart rhythm problems with lamotrigine in patients with heart disease. FDA safety communication.
U.S. Food and Drug Administration (FDA). (2025). LAMICTAL (lamotrigine): FDA-approved prescribing information, revised October 2025. Official labeling.
U.S. National Institute of Mental Health (NIMH). (n.d.). Bipolar disorder. Official overview.